U.S. Health Secretary Robert F. Kennedy Jr. has named eight new members to the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), following the abrupt dismissal of all 17 prior members. The newly appointed panel includes several figures known for expressing skepticism about vaccines, particularly mRNA technology.
Among the new appointees is Robert Malone, a vocal critic of mRNA COVID-19 vaccines and an ally of Kennedy’s "Make America Healthy Again" movement. Other members include Joseph Hibbeln, Martin Kulldorff, Retsef Levi, Cody Meissner, James Pagano, Vicky Pebsworth, and Michael Ross—some of whom have ties to prior CDC or FDA vaccine panels, while others have promoted views critical of current vaccination practices.
Kennedy, who has long challenged vaccine safety despite scientific consensus, claimed the former panel had conflicts of interest, although he did not provide specific evidence. He emphasized the reshuffle was meant to “restore public trust in vaccine science.”
The new ACIP members will participate in the committee’s June 25–27 meeting, where decisions are expected on vaccine recommendations for flu shots and the 2025–26 COVID-19 boosters. The meeting agenda has yet to be released.
The move sparked market reactions: Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) shares dipped slightly, while Novavax (NASDAQ:NVAX), which produces a non-mRNA COVID-19 vaccine, saw a marginal rise.
Concerns remain about the vetting process for the new members. Some, like Pebsworth and Meissner, have served on FDA advisory committees, while others, such as Levi and Kulldorff, have made controversial statements questioning mRNA vaccine safety.
Despite FDA confirmation that mRNA vaccines are safe and effective, Kennedy’s overhaul has intensified the national debate on vaccine policy and public health strategy.


Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing
U.S.–Venezuela Relations Show Signs of Thaw as Top Envoy Visits Caracas
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Rafah Border Crossing to Reopen for Palestinians as Israel Coordinates with Egypt and EU
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom
U.S. Accuses Cuba of Harassing Top Diplomat Amid Rising Tensions
Syria-Kurdish Ceasefire Marks Historic Step Toward National Unity
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use
Venezuela Proposes Amnesty Law and Plans to Transform Helicoide Prison
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 



